Journal
CLINICS IN LABORATORY MEDICINE
Volume 29, Issue 1, Pages 87-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cll.2009.01.005
Keywords
Proteomics; Biomarkers; Cardiac markers; Multiplex assays; Discovery; Validation; Translational research
Categories
Funding
- National Heart Lung Blood Institute Proteomic Initiative [N01-HV-28,120]
- SCCOR program (Specialized Centers of Clinically Oriented Research) [1 P50 HL 084,946-01]
- Clinical Translational Science [1U54RR023561-01A1]
- Daniel P. Amos Foundation
- Novartis Research Foundation
- Swiss National Science Foundation [PBSKP3-124604]
- Swiss National Science Foundation (SNF) [PBSKP3-124604] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Proteomics is fulfilling its potential and beginning to impact the diagnosis and therapy of cardiovascular disease. As de novo proteomics analysis gets more streamlined, and robust high-throughput methods are developed, more and more attention is being directed toward the field of cardiovascular serum and plasma biomarker discovery. To take cardiovascular proteomics from bench to bedside, great care must be taken to achieve reproducible results. Despite technical advances, however, the absolute number of clinical biomarkers thus far discovered by a proteomics approach is small. Although several factors contribute to this lack, one step is to build translation teams involving a close collaboration between researchers and clinicians.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available